



# William Pomerantz

William Pomerantz has been a professor in the Department of Chemistry at the University of Minnesota since 2012. He is also an affiliate faculty member in the Department of Medicinal Chemistry and one of the founding members of the Epigenetics Consortium on campus. Before coming to the University of Minnesota, he was a National Institutes of Health post-doctoral research fellow at the University of Michigan. He earned his doctorate in organic chemistry from the University of Wisconsin-Madison, spent a year as a Seydel/Fulbright Fellow at the Swiss Federal Institute of Technology in Zurich, Switzerland, and earned his bachelor's degree in chemistry from Ithaca College.

Pomerantz' research focuses on understanding the molecular mechanisms of epigenetic regulation while developing new chemical probes for transcription-factor protein interactions. His projects meld organic chemistry, biochemistry, biophysics and cellular biology approaches to achieve these goals. One distinguishing aspect of his research includes a protein-based fluorine NMR approach, which his lab has been applying for small molecule discovery. This work has led to the discovery of several novel inhibitors of bromodomain-containing proteins, which his group is studying in more detail in the context of breast cancer and heart disease.

His work is highly collaborative and includes a variety of academic research labs focusing on epigenetics research both within an outside the University of Minnesota as well as an industrial collaboration with Eli Lilly. His work has been published in some of the American Chemical Society's top publications as well as two recent publications at Nature Chemical Biology and Nature Protocols. It has also earned him a number of honors, including the National Science Foundation CAREER Award, the University of Minnesota McKnight Land-Grant Professorship, being named a 2016 Cottrell Scholar, grants from the American Cancer Society, American Heart Association, Sidney Kimmel Cancer Foundation, Masonic Cancer Center, Phi Kappa Phi, and an honorarium from Eli Lilly.

